



www.genfit.com

GENFIT ANNOUNCES ITS ANNUAL GENERAL SHAREHOLDERS' MEETING ON JUNE 26, 2013

Lille (France), Boston (Massachusetts, United States), May 22, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that it will hold a Combined General Shareholders' Meeting on June 26, 2013, at 10:30 a.m., at the Company's headquarters, situated at 885 avenue Eugène Avinée, 59120 Loos, France.

The Meeting announcement, that serves as an invitation to attend the meeting, is published today in the BALO (French Gazette of Obligatory Legal Announcements). This announcement, that may also be consulted on the company's web-site (www.genfit.com), contains the agenda and the text of the resolutions of the ordinary and extraordinary meeting that are to be put to the vote of the shareholders at the Annual General Meeting (AGM). The documentation concerning this AGM is available to shareholders subject to the conditions specified by the regulations in force, and may be consulted on the Company's web-site.

Jean-François Mouney, Chairman and CEO of GENFIT, declared: *"The proposed agenda will notably enable, as is the case every year, to present to our shareholders the Company's results and perspectives. Moreover, the Meeting will also enable the renewal of a certain number of member mandates of the Company's Supervisory Board, and will authorize the Management Board to initiate a program to buy back its own shares, in order to increase share liquidity, via a liquidity agreement.*

Following the significant reinforcement of the Company's capital announced in April of this year, and in line with the announcement made following this operation, we will also ask the Meeting to deliberate on the granting of power to the Management Board, authorizing a possible capital increase open to all shareholders. Such an operation would enable shareholders to participate, by exercising their preferential subscription rights, in a capital-raising operation of up to 5 million Euros (emission premium included). If a majority of the shareholders vote favorably to grant this delegation, the Management board will decide in the fall on the opportunity of undertaking this operation under similar discount conditions as those of the previous operation."

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr